Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ixabepilone
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 69 for your search:
Start Over
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA163-046, NCT00080301
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA163-048, NCT00082433
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Tissue collection/Repository, Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: PACS08 - UC-0140/0610, PACS-08/0610, 2006-006494-24, PACS08-Tavlx, BMS-UNICANCER-PACS-08/0610, AMGEN-UNICANCER-PACS-08/0610, FNCLCC-PACS-08/0610, FNCLCC-PACS 08/0610 – TavIx, EU-20804, FNCLCC-Tavlx, BMS-FNCLCC-PACS-08/0610, AMGEN-FNCLCC-PACS-08/0610, NCT00630032
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00476, CTSU 40502, NCCTG N063H, CDR0000617539, CALGB 40502, U10CA031946, U10CA180821, NCT00785291
A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI BRE 145, TITAN, NCT00789581
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11-PIR-11, NCT01492101
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03016, NABTT 2111, CDR257118, U01CA062475, JHOC-NABTT-2111, NCT00045708
BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02523, UPCC-04302, NCI-5787, CDR0000276716, 5787, NCT00057850
Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000393439, AECM-03099, AECM-CA163402, AECM-NMC-03-10-277C, NCT00096317
Ixabepilone and Liposomal Doxorubicin in Treating Women With Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00140, 0504007857, CDR0000441122, 7229, N01CM62204, P30CA013330, AECM-0504007857, NCI-7229, NCT00182767
Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy and Chemotherapy
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00155, 055513, CDR0000481121, N01CM62202, UCSF-055513, NCI-7347, 7347, NCT00331344
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI BRE 138, NCT00825734
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ALSSMBC0804, NCT00924352
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000256355, NCI-02-C-0229, NCI-5791, 5791, NCT00045097
Phase II Study of Ixabepilone in Patients With Relapsed or Refractory Indolent Lymphoproliferative Disorders
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-02046, NCI-5342, 5342, NCT00052572
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00031, NCI-5913, UCCRC-NCI-5913, CDR0000285683, UCCRC-11965B, 11965B, 5913, P30CA014599, N01CM62202, N01CM62201, NCT00058019
Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2012-02526, UCSF-02555, N01CM62206, CDR0000285731, NCI-6046, UCSF-H6872-22147-01, 6046, NCT00058084
Phase II Study of Ixabepilone in Patients With Metastatic Cisplatin-Refractory Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MSKCC-03041, NCI-6022, 6022, NCT00070096
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA163-081, NCT00080262
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00548, CDR0000372946, E3803, U10CA021115, ECOG-E3803, NCT00087139
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2012-02628, CDR0000391849, GOG-0129P, U10CA027469, NCT00095979
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02669, 13850A, N01CM62201, N01CM62209, CDR0000440071, UCCRC-13850A, 7084, NCI-7084, NCT00182702
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 1 to 35 at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2012-01826, COG-ADVL0524, CDR0000472912, NCI-P6451, NCI-06-C-0146, ADVL0524, U10CA098543, NCT00331643
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA163-115, NCT00370552
Start Over